Related Experiment Video
Updated: May 7, 2026
08:04
Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
RLIP76 Gene Variants are not Associated with Drug Response in Turkish Epilepsy Patients
E Manguoğlu1, S Akdeniz, No Dündar
1Department of Medical Biology, Faculty of Medicine, Akdeniz University, Antalya, Turkey.
Balkan Journal of Medical Genetics : BJMG
|September 21, 2013
Summary
Genetic variations in the RLIP76 gene are not linked to drug resistance in epilepsy patients. This study found no significant correlation between RLIP76 sequence variants and treatment outcomes in Turkish epilepsy cases.
Area of Science:
- Genetics
- Pharmacology
- Neurology
Background:
- Epilepsy affects millions, with a significant portion experiencing drug resistance.
- The RalA binding protein 1 (RALBP1/RLIP76) is implicated in multidrug resistance mechanisms in epilepsy.
Purpose of the Study:
- To investigate polymorphic differences in the RLIP76 gene in Turkish epilepsy patients.
- To determine if sequence variants in RLIP76 are associated with drug resistance in epilepsy.
Main Methods:
- Analyzed coding regions and exon-intron boundaries of the RLIP76 gene.
- Utilized denaturing high-performance liquid chromatography (HPLC) and sequencing analysis.
- Compared variants between 146 refractory and 155 non-refractory epileptic patients.
Main Results:
- Identified several sequence variants in the RLIP76 gene (e.g., c.160-4G>A, c.187C>G).
- No statistically significant correlation was found between RLIP76 allele frequencies and drug response status.
Conclusions:
- Sequence variants in the RLIP76 gene are not a contributing factor to drug resistance in epilepsy.
- Further research may explore other genetic or non-genetic factors influencing epilepsy treatment outcomes.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...